oncology-cancer-therapy-2019-keynote

3 / 11

Page 14
allied
academies
Journal of Medical Oncology & Therapeutics | Volume 4
Oncology & Cancer Therapy
International Conference on
March 18-19, 2019 | London, UK
Statement of the Problem: Cancer cells desensitize themselves
to circumvent interventions. Consequently, apoptosis index
(AI, Apoptosis level) gets reduced making them opaque to
treatments. Methods are needed to improve the extent
response from treatments and to predict which treatment
works better for which patients.
Potential Solution: The potential solution would be to a)
enhance the cell death selectively in tumor, image cell death
in tumor, measure AI using non-invasive imaging technology
SPECT, PET, Ultrasound and MRI), b) sensitize low and non-
responsive tumors using AAAPT technology and c) use AI as a
biomarker to predict the efficacy of treatments.
Results: The leading AAAPT drug molecules sensitized cancer
stem cells and low-responsive tumor cells by reducing the IC-
50 of several FDA approved drugs (e.g. doxorubicin, paclitaxel,
gemcitabine)by10-15timesinvitro.Asaresult,thecombination
of AAAPT with chemotherapy achieved tumor regression in an
in vivo xenograft triple negative breast cancer (TNBC) tumor
model at a much lower dose of chemotherapy and reduced
dose resulted cardiotoxicity. SPECT-CT images showed an
increase in apoptosis in tumor selectively (increasing efficacy),
while reduced the cell death in heart (reducing cardiotoxicity).
The potential mechanism of drug action is depicted in the
image attached.
Conclusion and Significance: Imaging spontaneous tumor
apoptosis index permitted the risk stratification of patients as
to who responds better to which treatments based on tumor
AI. The broader significance of AAAPT is that it can, potentially
be used as a neoadjuvant to chemotherapy, radiation therapy,
immunotherapy or radionuclide therapy and clinically
translatable for a better management of cancer patients.
Reference: Raghu Pandurangi: A priori Activation of Apoptosis
Pathways of Tumor Technology (AAAPT) for Enhancing Tumor
Cell Response to Anticancer Agent, Jan 2016, PCT/US16/68554.
Speaker Biography
Raghu Pandurangi started his scientific career PhD in spectroscopy followed by post-
doctoral training at Radiology and Internal medicine, University of Missouri, Columbia
where he remained as a faculty for 10 years. He was a principle investigator position in
Shering AG, Germany where he directed and involved in 2 FDA approved drugs (AccuTect
and NeoTect). He was a team leader at Mallinckrodt directing apoptosis imaging. He
became an entrepreneur in 2013 inventing AAAPT technology for improving FDA approved
drugs.Currently,he istheFounder,PresidentandCSOofSci-Engi-MedcoSolutions(SEMCO)
and Amplexi-LLC, recipient of several NIH grants and awards.
e:
Raghu Pandurangi
Sci-Engi-Medco Solutions, USA
A prior activation of apoptosis pathways of tumor (AAAPT) technology: Biomarker for
the risk stratification of cancer patients
Notes: